Italia markets closed

Ascendis Pharma A/S (ASND)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
137,20-3,90 (-2,76%)
Alla chiusura: 04:00PM EDT
138,00 +0,80 (+0,58%)
Dopo ore: 05:12PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente141,10
Aperto141,96
Denaro136,80 x 200
Lettera137,53 x 100
Min-Max giorno135,16 - 142,36
Intervallo di 52 settimane83,75 - 161,00
Volume511.411
Media Volume338.479
Capitalizzazione7,767B
Beta (5 anni mensile)N/D
Rapporto PE (ttm)N/D
EPS (ttm)-9,51
Prossima data utili02 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A0,29
  • GlobeNewswire

    Ascendis Presents TransCon™ PTH Data at the American Thyroid Association Annual Meeting

    – At Week 26, 81% of patients in Phase 3 PaTHway Trial with chronic post-surgical hypoparathyroidism, the most common cause of this disease, achieved independence from conventional therapy while maintaining normocalcemia following treatment with TransCon PTH – Post-surgical patients treated with TransCon PTH self-reported significant improvements in disease-related symptoms, physical functioning, and daily life compared to those on placebo – Results for post-surgical patients (n=70) comparable t

  • GlobeNewswire

    Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone Deficiency

    - The majority of children and adolescents treated once weekly with TransCon hGH (lonapegsomatropin) met or exceeded average parental height SDS at time of treatment completion or last visit - Trial demonstrated the long-term safety of TransCon hGH in patients treated up to 6 years COPENHAGEN, Denmark, Sept. 23, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced results from enliGHten, the Company’s open-label extension trial evaluating the long-term safety and efficacy

  • GlobeNewswire

    Ascendis Pharma Launches SKYTROFA® (lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency

    COPENHAGEN, Denmark, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the launch in Germany of SKYTROFA® (lonapegsomatropin), its growth hormone approved in the European Union for the once-weekly treatment of children and adolescents ages 3 to 18 years with growth failure due to insufficient endogenous growth hormone secretion (growth hormone deficiency, or GHD). “SKYTROFA is designed to deliver unmodified somatropin, the same growth hormone used in daily ped